Literature DB >> 6517550

In vitro activity of ciprofloxacin against aerobic gram-negative bacteria.

J E Rudin, C W Norden, E M Shinners.   

Abstract

For 177 gram-negative isolates, the MICs for ciprofloxacin ranged from 0.02 microgram/ml (Escherichia coli) to 0.31 microgram/ml (Pseudomonas aeruginosa). In time-kill curves, ciprofloxacin at 8 X the MIC almost completely killed 10(6) CFU of P. aeruginosa by 24 h. Ciprofloxacin at 4 X the MIC allowed bacterial regrowth by 24 h, with development of partial resistance to ciprofloxacin.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6517550      PMCID： PMC179973          DOI： 10.1128/AAC.26.4.597

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  7 in total

1.  A method for testing for synergy with any number of agents.

Authors:  M C Berenbaum
Journal:  J Infect Dis       Date:  1978-02       Impact factor: 5.226

2.  Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria.

Authors:  N X Chin; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

3.  In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent.

Authors:  G M Eliopoulos; A Gardella; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

4.  In vitro activity of ciprofloxacin compared with those of other new fluorinated piperazinyl-substituted quinoline derivatives.

Authors:  D L Van Caekenberghe; S R Pattyn
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

5.  In vitro activity of ciprofloxacin (Bay o 9867).

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

6.  Comparative activities of ciprofloxacin (Bay o 9867), norfloxacin, pipemidic acid, and nalidixic acid.

Authors:  H L Muytjens; J van der Ros-van de Repe; G van Veldhuizen
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

7.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191
  7 in total
  15 in total

Review 1.  Synergy and antagonism of combinations with quinolones.

Authors:  H C Neu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

2.  In vitro activity of ciprofloxacin combined with azlocillin.

Authors:  J A Moody; L R Peterson; D N Gerding
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

3.  In vitro activity of trovafloxacin in combination with ceftazidime, meropenem, and amikacin.

Authors:  D Milatovic; C Wallrauch
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-08       Impact factor: 3.267

4.  In vivo bactericidal activities of ciprofloxacin and pefloxacin in an experimental model of Serratia marcescens endocarditis.

Authors:  M E Juvin; G Potel; J Caillon; Y Q Xiong; D Bugnon; P Le Conte; D I Baron; H B Drugeon
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

Review 5.  Synergy and antagonism of fluoroquinolones with other classes of antimicrobial agents.

Authors:  H C Neu
Journal:  Drugs       Date:  1993       Impact factor: 9.546

6.  Ciprofloxacin activity in cyst fluid from polycystic kidneys.

Authors:  L W Elzinga; T A Golper; A L Rashad; M E Carr; W M Bennett
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

7.  Treatment of bone, joint, and soft-tissue infections with oral ciprofloxacin.

Authors:  R N Greenberg; D J Kennedy; P M Reilly; K L Luppen; W J Weinandt; M R Bollinger; F Aguirre; F Kodesch; A M Saeed
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

8.  Comparative efficacies of ciprofloxacin and pefloxacin alone or in combination with fosfomycin in experimental endocarditis induced by multidrug-susceptible and -resistant Pseudomonas aeruginosa.

Authors:  Y Q Xiong; G Potel; J Caillon; G Stephant; F Jehl; D Bugnon; P Le Conte; D Baron; H Drugeon
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

9.  Comprehensive evaluation of ciprofloxacin-aminoglycoside combinations against Enterobacteriaceae and Pseudomonas aeruginosa strains.

Authors:  I Haller
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

Review 10.  Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; J P Monk; A Price; P Benfield; P A Todd; A Ward
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.